Valuation: Oncternal Therapeutics, Inc.

Market Cap 15.59L 13.7L 12.75L 11.71L 21.99L 15Cr 22.28L 1.52Cr 59.21L 7.38Cr 58.51L 57.25L 26Cr P/E 2022
-1.19x
P/E 2023 -0.8x
Enterprise Value -3.24Cr -2.85Cr -2.65Cr -2.43Cr -4.57Cr -310.51Cr -4.63Cr -31Cr -12Cr -153.32Cr -12Cr -12Cr -529.93Cr EV / Sales 2022
-4.9x
EV / Sales 2023 -2.95x
Free-Float
90.77%
Yield 2022 *
-
Yield 2023 -
3 years 0.53
Extreme 0.5266
13.14
5 years 0.53
Extreme 0.5266
92.6
10 years 0.53
Extreme 0.5266
211.2
Manager TitleAgeSince
Director of Finance/CFO 63 01/04/2017
Chief Tech/Sci/R&D Officer - 01/07/2023
Chief Tech/Sci/R&D Officer 53 -
Director TitleAgeSince
Chairman 77 01/12/2018
Director/Board Member 79 07/06/2019
Director/Board Member 75 01/12/2017
Date Insider Type Main position Quantity % Market Cap.
20/06/24 Free

Director

2,200 0.0743%
20/06/24 Free

Director

2,200 0.0743%
20/06/24 Free

Director

2,200 0.0743%
Change 5-day change 1-year change 3-year change Capi.($)
-24.11%-.--%-.--%-92.96% 15.59L
-0.25%-0.78%-0.99%+10.90% 4.77TCr
-0.61%+4.26%+396.16%+647.20% 4TCr
0.00%+4.93%+11.81%+55.56% 3.62TCr
+2.48%+4.57%+7.05%-5.05% 3.56TCr
+0.62%+3.53%+5.41%+42.19% 2.79TCr
-0.17%+0.66% - - 1.67TCr
-2.00%+11.64%+31.71%+136.81% 1.65TCr
+0.06%-3.88%+2.35%+7.45% 1.32TCr
+1.82%+1.56%-9.75%-30.15% 1.29TCr
Average -1.33%-0.09%+49.31%+85.77% 2.47TCr
Weighted average by Cap. +1.34%+2.94%+74.11%+136.35%

Financials

2022 2023
Net sales 14.9L 13.1L 12.19L 11.2L 21.03L 14Cr 21.3L 1.45Cr 56.61L 7.06Cr 55.93L 54.73L 24Cr 8L 7L 6L 6L 11.08L 7.53Cr 11.22L 76.36L 29.82L 3.72Cr 29.47L 28.83L 13Cr
Net income -4.42Cr -3.88Cr -3.61Cr -3.32Cr -6.23Cr -423.59Cr -6.32Cr -43Cr -17Cr -209.16Cr -17Cr -16Cr -722.93Cr -3.95Cr -3.47Cr -3.23Cr -2.97Cr -5.57Cr -378.6Cr -5.64Cr -38Cr -15Cr -186.95Cr -15Cr -15Cr -646.15Cr
Net Debt -6.36Cr -5.59Cr -5.21Cr -4.78Cr -8.98Cr -610.27Cr -9.1Cr -62Cr -24Cr -301.34Cr -24Cr -23Cr -1.04TCr -3.39Cr -2.98Cr -2.78Cr -2.55Cr -4.79Cr -325.45Cr -4.85Cr -33Cr -13Cr -160.7Cr -13Cr -12Cr -555.44Cr
Logo Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Employees
29
  1. Stock Market
  2. Stocks
  3. ONCT Stock